FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

COHANCE LIFESCIENCES LTD.

NSE : COHANCEBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private

BSE1011.2088.1 (+9.54 %)

PREV CLOSE (Rs.) 923.10

OPEN PRICE (Rs.) 943.80

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 140049

TODAY'S LOW / HIGH (Rs.)915.10 1038.00

52 WK LOW / HIGH (Rs.)856.9 1359

NSE1012.9590.05 (+9.76 %)

PREV CLOSE( Rs. ) 922.90

OPEN PRICE (Rs.) 937.70

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1012.95 (12565)

VOLUME 4938667

TODAY'S LOW / HIGH(Rs.) 914.25 1038.90

52 WK LOW / HIGH (Rs.)856.3 1360

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

1393.84

Dividend Yield(%)

0.00

TTM EPS (Rs.)

6.79

P/E Ratio

149.02

Book Value (Rs.)

61.79

Face Value (Rs.)

MCap (Rs. in Mn)

386851.89

Price/Earning (TTM)

116.57

Price/Sales (TTM)

29.19

Price/Book (MRQ)

16.36

PAT Margin (%)

24.85

ROCE (%)

16.14

Incorporation Year : 06-11 2018

Management Info :

Vivek Sharma - Chairman V Prasada Raju - Managing Director

Registered Office :

Address : 215 Atrium, C Wing, 8th Floor, 819-821,Andheri, Kurla Road, Chakala,Andheri (East), Chakala Midc,
Mumbai,
Maharashtra-400093

Phone : 022-61539999

Email : info@suvenpharm.com

Website : www.suvenpharm.com

Registrars Details :

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

14Aug USFDA completes GMP inspection at Coha
United States Food and Drug Administration (USFDA) has completed a Good..

12Aug Cohance Lifesciences to invest $10 mil
Cohance Lifesciences (with its subsidiaries, hereafter referred to as ‘C..

20Jun Cohance Lifesciences enters into agree
Cohance Lifesciences has entered into an agreements with Chromo Laborato..

Financials

	QTR Jun 25	ANNUAL 25
Net Profit	525.7	2717.1
Gross Profit	710.4	3513.5
Operating Profit	1173	4165.5
Net Sales	4835.8	10935.1

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Procter&Gamble Healt (BSE)

6525.95 (0.94%)

M.Cap (Rs. in Cr)10832.67

Glaxosmithkline Phar (BSE)

2820.85 (1.82%)

M.Cap (Rs. in Cr)47786.90

Haleos Labs (BSE)

1165.65 (4.22%)

M.Cap (Rs. in Cr)352.41

Caplin Point Lab (BSE)

2176.05 (1.86%)

M.Cap (Rs. in Cr)16540.53

Shareholding Pattern

	PROMOTERS	66.41%
	NON-INSTITUTION	14.95%
	MUTUAL FUNDS/UTI	8.9%
	FI/BANKS/INSURANCE	2.27%
	GOVERNMENT	0.01%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

DSP Healthcare Fund...

7.88

ITI Pharma & Health...

4.53

Mirae Asset Healthc...

3.61

UTI Healthcare Fund...

2.81

HDFC Pharma and Hea...

2.24

DSP Focused Fund-Reg(G)

2.17

Invesco India Focus...

2.17

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22

COHANCE LIFESCIENCES LTD.

Smart Quotes

Attention Investors

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Filing complaints on SCORESEasy & quick

Risk Disclosures On Derivatives